A Novel Equation for Estimating Sodium Intake in Peritoneal Dialysis.
The Development and Validation of a Novel Equation for Estimating Sodium Intake in Peritoneal Dialysis
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Jie Dong, Professor
- Phone Number: 13911841538
- Email: jie.dong@bjmu.edu.cn
Study Contact Backup
- Name: Lulu Jing
- Phone Number: 15201304983
- Email: jingll_wit@bjmu.edu.cn
Study Locations
-
-
-
Beijing, China
- Peking University First Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Peritoneal dialysis vintage >3 months.
- 18-80 years old.
- No residual renal function (urine volume<200ml/day).
Exclusion Criteria:
- Peritonitis in the past month.
- Acute systemic infection, cardio-cerebrovascular complications and surgical trauma in the past month.
- Uncorrected hyponatremia (blood sodium<130mmol/L).
- Prescribed with sodium bicarbonate.
- Prescribed with glucocorticoids and aldosterone antagonists.
- Dysfunction of peritoneal dialysis catheter.
- Malignant tumor receiving radiotherapy and chemotherapy, severe dyspepsia or eating disorder.
- Body fluid loss due to vomit, diarrhea, massive sweating, or other causes.
- Cannot follow the research scheme.
- Refuse to participate in this study.
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
determination coefficient of the novel equation
Time Frame: July 3, 2023, to March 1, 2024
|
Determination coefficient will be assessed as the square of the multiple correlation coefficient of the novel equation for estimating sodium intake in peritoneal dialysis.
|
July 3, 2023, to March 1, 2024
|
|
bias of the novel equation
Time Frame: July 3, 2023, to March 1, 2024
|
Bias will be assessed as the median of the difference between the estimated and measured dietary sodium values.
|
July 3, 2023, to March 1, 2024
|
|
precision of the novel equation
Time Frame: July 3, 2023, to March 1, 2024
|
Precision will be assessed as the standard deviation (SD) for the absolute value of difference between the estimated and measured dietary sodium values.
|
July 3, 2023, to March 1, 2024
|
|
accuracy of the novel equation
Time Frame: July 3, 2023, to March 1, 2024
|
Accuracy will be assessed as the percentage of estimates that differed >20% from the measured dietary sodium values (1-P20) .
|
July 3, 2023, to March 1, 2024
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Jie Dong, Professor, Peking University First Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- 2022SF38
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.